MCM
AMAM

Moore Capital Management’s Ambrx Biopharma Inc AMAM Stock Holding History

Moore Capital Management’s Portfolio AMAM Stock Details AMAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-144,400
Closed -$2.38M – 615
2023
Q2 		$2.38M Buy
+144,400
New +$1.82M 0.04% 240

Other funds holding AMAM

DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Moore Capital Management's AMAM Position: Q3 2023 in Review

Moore Capital Management sold out of Ambrx Biopharma Inc (AMAM) in Q3 2023, closing a stake of 144,400 shares — an estimated $2.38M sold.

Moore Capital Management first reported a position in AMAM in Q2 2023 and held it in 1 quarter. The position peaked at $2.38M in Q2 2023. 44 funds tracked by Wall St. Rank hold AMAM as of Q3 2023.

  • Moore Capital Management reported no remaining Ambrx Biopharma Inc position as of Q3 2023 after selling out during the quarter.
  • Moore Capital Management sold 144,400 Ambrx Biopharma Inc shares in Q3 2023, an estimated $2.38M.
  • Moore Capital Management first reported a position in Ambrx Biopharma Inc in Q2 2023 and held it in 1 quarter.
  • Moore Capital Management's Ambrx Biopharma Inc position peaked at $2.38M in Q2 2023.
  • 44 funds tracked by Wall St. Rank held Ambrx Biopharma Inc as of Q3 2023.

Based on Moore Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.